百时美施贵宝(Bristol-Myers Squibb)公布的数据显示,其药物组合Iza-Bren在重度经治的患者群体中表现出可控的安全性特征。研究期间,未观察到任何新的安全信号。这一结果对于此前已接受过多种治疗方案的患者而言,具有积极的临床意义。
百时美施贵宝(Bristol-Myers Squibb)公布的数据显示,其药物组合Iza-Bren在重度经治的患者群体中表现出可控的安全性特征。研究期间,未观察到任何新的安全信号。这一结果对于此前已接受过多种治疗方案的患者而言,具有积极的临床意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.